Literature DB >> 15203322

Fluorescein isothiocyanate-hapten immunoassay for determination of peptide-cell interactions.

Kimberly A Kelly1, Fred Reynolds, Ralph Weissleder, Lee Josephson.   

Abstract

We have developed a fluorescein isothiocyanate (FITC)-hapten immunoassay, where a FITC-labeled peptide binding to a cell is assayed as the amount of immunoreactive fluorescein present in a cell lysate. An antifluorescein-horseradish peroxidase conjugate binds to either a fluoresceinated peptide in the lysate or a fluorescein attached to the wells of a microtiter plate in a competitive fashion. After washing, solid-phase peroxidase activity is measured and inversely related to the amount of FITC-labeled peptide present. To demonstrate the assay, the interaction of a FITC-labeled bombesin-like peptide with the gastrin-releasing peptide receptor on PC-3 and HT-29 cells was investigated. Using PC-3 cells, we obtained similar displacement curves and numbers of binding sites per cell by both the FITC-hapten immunoassay and a reference radioreceptor assay. The FITC-hapten immunoassay is a sensitive and versatile method, since the same commercially available reagents can be used to assess interactions between any peptide and any receptor. In addition, the FITC-labeled peptide can be used to visualize receptors in fluorescent-activated cell sorting or fluorescent microscopy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15203322     DOI: 10.1016/j.ab.2004.02.035

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  5 in total

1.  Nanoparticle imaging of integrins on tumor cells.

Authors:  Xavier Montet; Karin Montet-Abou; Fred Reynolds; Ralph Weissleder; Lee Josephson
Journal:  Neoplasia       Date:  2006-03       Impact factor: 5.715

2.  Unbiased discovery of in vivo imaging probes through in vitro profiling of nanoparticle libraries.

Authors:  Kimberly A Kelly; Stanley Y Shaw; Matthias Nahrendorf; Kelly Kristoff; Elena Aikawa; Stuart L Schreiber; Paul A Clemons; Ralph Weissleder
Journal:  Integr Biol (Camb)       Date:  2009-02-09       Impact factor: 2.192

3.  A wortmannin-cetuximab as a double drug.

Authors:  R Adam Smith; Hushan Yuan; Ralph Weissleder; Lewis C Cantley; Lee Josephson
Journal:  Bioconjug Chem       Date:  2009-11       Impact factor: 4.774

4.  Rhodamine-marked bombesin: a novel means for prostate cancer fluorescence imaging.

Authors:  Alexander Sturzu; Sumbla Sheikh; Hartmut Echner; Thomas Nägele; Martin Deeg; Bushra Amin; Christian Schwentner; Marius Horger; Ulrike Ernemann; Stefan Heckl
Journal:  Invest New Drugs       Date:  2013-06-01       Impact factor: 3.850

5.  Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design.

Authors:  D Sean Froese; Amit Michaeli; Thomas J McCorvie; Tobias Krojer; Meitav Sasi; Esther Melaev; Amiram Goldblum; Maria Zatsepin; Alexander Lossos; Rafael Álvarez; Pablo V Escribá; Berge A Minassian; Frank von Delft; Or Kakhlon; Wyatt W Yue
Journal:  Hum Mol Genet       Date:  2015-07-21       Impact factor: 6.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.